#BEGIN_DRUGCARD DB02524

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C16H16N8O19P3

# Chemical_IUPAC_Name:
O-{[4'-(6-amino-9H-purin-9-yl)-6'-({[hydroxy({[hydroxy(phosphonooxy)phosphoryl]oxy})phosphoryl]oxy}methyl)-2,6-dinitro-3'a,4',6',6'a-tetrahydrospiro[cyclohexane-1,2'-furo[3,4-d][1,3]dioxole]-2,5-dien-4-ylidene]nitroso}oxidanidolate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Spiro(2,4,6-Trinitrobenzene[1,2a]-2o',3o'-Methylene-Adenine-Triphosphate

# HET_ID:
128

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C16H16N8O19P3/c17-13-10-14(19-4-18-13)21(5-20-10)15-12-11(7(39-15)3-38-45(34,35)43-46(36,37)42-44(31,32)33)40-16(41-12)8(23(27)28)1-6(22(25)26)2-9(16)24(29)30/h1-2,4-5,7,11-12,15H,3H2,(H6-,17,18,19,25,26,31,32,33,34,35,36,37)/q-1

# InChI_Key:
InChIKey=LQZBDVDATBCNNN-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2524

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
717.2617

# Molecular_Weight_Mono:
716.974454906

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1I5D

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0.16

# Predicted_LogS:
-2.4

# Predicted_Water_Solubility:
3.22e+00 g/l

# Primary_Accession_No:
DB02524

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
46507848

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00019

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=NC=NC2=C1N=CN2C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C2OC3(OC12)C(=CC(C=C3[N+]([O-])=O)=N([O-])=O)[N+]([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:21:13 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm (Potential)

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
U30501

# Drug_Target_1_GenBank_ID_Protein:
940146

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
cheA

# Drug_Target_1_Gene_Sequence:
>2016 bp
ATGATGGAAGAATATCTCGGAGTGTTTGTCGATGAGACAAAAGAATACCTTCAAAATCTG
AACGATACCCTCCTCGAATTGGAGAAAAATCCCGAAGATATGGAACTCATAAACGAAGCG
TTCAGGGCTCTTCATACCCTGAAAGGAATGGCAGGTACAATGGGGTTTTCCAGTATGGCG
AAGCTCTGCCATACCTTAGAAAACATCCTCGATAAAGCCAGAAACAGCGAGATAAAGATA
ACTTCCGATCTCCTCGATAAGATCTTCGCGGGGGTCGATATGATAACCAGAATGGTTGAT
AAGATCGTCTCCGAGGGAAGTGACGACATCGGAGAAAACATAGACGTGTTCTCCGACACC
ATAAAAAGCTTTGCATCATCGGGAAAAGAGAAGCCTTCAGAAATCAAAAATGAAACGGAA
ACAAAGGGTGAGGAAGAACACAAAGGAGAATCAACAAGCAATGAAGAAGTCGTAGTTCTT
CCTGAAGAAGTTGCCCACGTTCTTCAGGAAGCGAGAAACAAGGGTTTCAAAACGTTTTAT
ATTAAAGTGATTCTCAAAGAAGGAACGCAGTTGAAATCCGCCAGGATTTACCTCGTTTTC
CACAAGCTTGAAGAACTGAAGTGTGAAGTTGTGAGAACGATTCCTTCGGTTGAAGAGATA
GAAGAAGAGAAATTCGAAAACGAAGTGGAACTCTTCGTAATCTCCCCTGTGGATCTGGAG
AAACTCTCTGAAGCTCTGTCAAGCATCGCCGATATAGAGAGGGTAATAATAAAAGAAGTA
ACCGCCGTCACCGAAGAATCAGGGGCTGAGAAAAGAACCGAGAAAGAAGAGAAAACTGAA
AAAACTGAGGAAAAGGCCGAAAGAAAAAAGGTTATTTCGCAAACAGTCAGGGTAGATATA
GAGAAACTGGGCAATTTGATGGATTTGATGGGAGAACTGGTCATCGCAAGGAGCAGAATA
CTGGAAACGCTCAAGAAATACAACATAAAAGAACTGGATGAGAGTTTGTCTCATCTCAGC
AGGATCACCTTAGACCTTCAGAATGTTGTGATGAAGATCAGAATGGTTCCCATCTCCTTT
GTTTTCAACAGATTCCCTCGAATGGTGAGAGACCTTGCCAAAAAGATGAACAAAGAAGTG
AATTTCATCATGAGAGGAGAAGACACAGAGCTCGACAGAACGTTCGTTGAAGAAATTGGC
GAACCCCTGCTCCATCTCCTGAGAAACGCCATCGACCACGGTATAGAACCCAAAGAAGAA
CGAATAGCCAAAGGAAAACCCCCCATTGGAACACTCATTCTCTCGGCACGTCACGAGGGA
AACAACGTGGTAATAGAAGTCGAAGATGACGGAAGGGGTATAGACAAGGAAAAGATCATC
AGAAAAGCCATAGAAAAGGGACTCATAGATGAATCAAAGGCCGCTACCCTTTCTGATCAG
GAGATTCTGAACTTCCTCTTCGTTCCGGGATTCTCCACAAAGGAAAAAGTCTCAGAAGTC
TCCGGAAGAGGCGTGGGAATGGATGTCGTGAAAAATGTGGTGGAATCTTTGAATGGTAGC
ATAAGCATAGAAAGCGAGAAAGATAAAGGAACAAAAGTTACGATAAGACTACCGCTCACT
CTGGCCATCATTCAGGCGCTCCTCGTCAAAGTCAACAATCTCGTCTACGCGATTCCGATA
GCGAACATAGACACAATACTCAGCATTTCAAAAGAGGATATTCAAAGAGTTCAGGACAGA
GATGTGATAGTCATAAGAGGAGAAGTGATACCCGTTTACCGTCTGTGGGAAGTGCTTCAA
ATAGAGCACAAAGAAGAACTGGAGGAGATGGAAGCGGTTATTGTGAGGGTAGGAAACAGG
AAGTACGGTATCGTCGTAGACGATCTTCTCGGTCAGGACGATATCGTGATAAAATCTCTT
GGAAAGGTGTTCTCTGAGGTGAAGGAATTCAGCGGAGCAGCTATTCTCGGTGATGGTAGT
ATAGCGCTGATAATCAACGTCTCCGGCATTGTATAA

# Drug_Target_1_General_Function:
Signal transduction mechanisms

# Drug_Target_1_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.
8550470	Swanson RV, Sanna MG, Simon MI: Thermostable chemotaxis proteins from the hyperthermophilic bacterium Thermotoga maritima. J Bacteriol. 1996 Jan;178(2):484-9.
9989504	Bilwes AM, Alex LA, Crane BR, Simon MI: Structure of CheA, a signal-transducing histidine kinase. Cell. 1999 Jan 8;96(1):131-41.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2615

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
75557

# Drug_Target_1_Name:
Chemotaxis protein cheA

# Drug_Target_1_Number_of_Residues:
671

# Drug_Target_1_PDB_ID:
1B3Q

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01584	CheW
PF01627	Hpt
PF02518	HATPase_c
PF02895	H-kinase_dim
PF07194	P2

# Drug_Target_1_Protein_Sequence:
>Chemotaxis protein cheA
MMEEYLGVFVDETKEYLQNLNDTLLELEKNPEDMELINEAFRALHTLKGMAGTMGFSSMA
KLCHTLENILDKARNSEIKITSDLLDKIFAGVDMITRMVDKIVSEGSDDIGENIDVFSDT
IKSFASSGKEKPSEIKNETETKGEEEHKGESTSNEEVVVLPEEVAHVLQEARNKGFKTFY
IKVILKEGTQLKSARIYLVFHKLEELKCEVVRTIPSVEEIEEEKFENEVELFVISPVDLE
KLSEALSSIADIERVIIKEVTAVTEESGAEKRTEKEEKTEKTEEKAERKKVISQTVRVDI
EKLDNLMDLMGELVIARSRILETLKKYNIKELDESLSHLSRITLDLQNVVMKIRMVPISF
VFNRFPRMVRDLAKKMNKEVNFIMRGEDTELDRTFVEEIGEPLLHLLRNAIDHGIEPKEE
RIAKGKPPIGTLILSARHEGNNVVIEVEDDGRGIDKEKIIRKAIEKGLIDESKAATLSDQ
EILNFLFVPGFSTKEKVSEVSGRGVGMDVVKNVVESLNGSISIESEKDKGTKVTIRLPLT
LAIIQALLVKVNNLVYAIPIANIDTILSISKEDIQRVQDRDVIVIRGEVIPVYRLWEVLQ
IEHKEELEEMEAVIVRVGNRKYGIVVDDLLGQDDIVIKSLGKVFSEVKEFSGAAILGDGS
IALIINVSGIV

# Drug_Target_1_Reaction:
ATP + protein L-histidine = ADP + protein N-phospho-L-histidine

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Involved in the transmission of sensory signals from the chemoreceptors to the flagellar motors. CheA is autophosphorylated; it can transfer its phosphate group to either cheB or cheY

# Drug_Target_1_SwissProt_ID:
Q56310

# Drug_Target_1_SwissProt_Name:
CHEA_THEMA

# Drug_Target_1_Synonyms:
EC 2.7.13.3

# Drug_Target_1_Theoretical_pI:
4.64

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB02524
